Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab

Results to be presented for the first time show mosunetuzumab induces high and durable complete response rates in people with follicular lymphoma who have received two or more prior therapies1 New efficacy data from Roche’s portfolio of cancer immunotherapies demonstrate potential of bispecific antibodies to expand upon current treatment options across several blood cancers Basel,... Read more

New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq

After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free survival improvement for the combination compared with Tecentriq alone CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell... Read more

New Sample Preparation Solution Simplifies Food Safety Testing

The Thermo Scientific QuEChERS portfolio delivers robust, sensitive quantitation in compliance with global regulatory requirements LANGERWEHE, Germany, Dec. 9, 2021 /PRNewswire/ — Food industry, government and contract testing laboratories performing food safety analysis can now benefit from a new portfolio that offers cost-effective, robust Solid-Phase Extraction (SPE) solutions to support food safety workflows and meet regulatory... Read more

FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue

FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue CARLSBAD, Calif., Dec. 9, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients... Read more

Covalent Metrology and JEOL Announce Partnership, Silicon Valley Demonstration Facility

The two leaders announced a partnership that includes a new JEOL demonstration facility located in Covalent’s Silicon Valley lab. The partnership will accelerate applications development and broaden client access to a suite of state-of-art instrumentation and analytical services. December 07, 2021 – Sunnyvale, CA. Covalent Metrology, a leading North American provider of analytical services, announces... Read more

Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

Thermo Fisher Scientific Completes Acquisition of PPD, Inc. WALTHAM, Mass., Dec. 8, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for... Read more

PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Surveillance

New NGS workflow accelerates the detection of SARS-CoV-2 variants including Omicron WALTHAM, Mass.–(BUSINESS WIRE)–Dec. 8, 2021– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced the research use only (RUO) launch of the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 to accelerate the detection of SARS-CoV-2 variants. This complete next... Read more

Bruker Announces $500 Million Private Placement of Senior Notes to Support Strategic Growth Objectives

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) announced today that it has completed a new private placement of 10-year senior notes in the aggregate principal amount of $500 million to enhance its financial flexibility and fund strategic growth objectives. Gerald Herman, Bruker’s Executive Vice President & Chief Financial Officer, commented “This new debt financing capitalizes... Read more